These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 23825587)

  • 1. Attenuated RORC expression in the presence of EMT progression in somatotroph adenomas following treatment with somatostatin analogs is associated with poor clinical recovery.
    Lekva T; Berg JP; Heck A; Lyngvi Fougner S; Olstad OK; Ringstad G; Bollerslev J; Ueland T
    PLoS One; 2013; 8(6):e66927. PubMed ID: 23825587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression profiling identifies ESRP1 as a potential regulator of epithelial mesenchymal transition in somatotroph adenomas from a large cohort of patients with acromegaly.
    Lekva T; Berg JP; Fougner SL; Olstad OK; Ueland T; Bollerslev J
    J Clin Endocrinol Metab; 2012 Aug; 97(8):E1506-14. PubMed ID: 22585092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epithelial splicing regulator protein 1 and alternative splicing in somatotroph adenomas.
    Lekva T; Berg JP; Lyle R; Heck A; Ringstad G; Olstad OK; Michelsen AE; Casar-Borota O; Bollerslev J; Ueland T
    Endocrinology; 2013 Sep; 154(9):3331-43. PubMed ID: 23825128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.
    Franck SE; Gatto F; van der Lely AJ; Janssen JAMJL; Dallenga AHG; Nagtegaal AP; Hofland LJ; Neggers SJCMM
    Neuroendocrinology; 2017; 105(1):44-53. PubMed ID: 27455094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative splicing of placental lactogen (CSH2) in somatotroph pituitary adenomas.
    Lekva T; Berg JP; Lyle R; Heck A; Bollerslev J; Ueland T
    Neuro Endocrinol Lett; 2015; 36(2):136-42. PubMed ID: 26071582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours.
    Plöckinger U; Hoffmann U; Geese M; Lupp A; Buchfelder M; Flitsch J; Vajkoczy P; Jakob W; Saeger W; Schulz S; Dohrmann C
    Eur J Endocrinol; 2012 Feb; 166(2):223-34. PubMed ID: 22065857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ghrelin receptor (GHS-R1a) and its constitutive activity in somatotroph adenomas: a new co-targeting therapy using GHS-R1a inverse agonists and somatostatin analogs.
    Mear Y; Blanchard MP; Defilles C; Brue T; Figarella-Branger D; Graillon T; Manavela M; Barlier A; Enjalbert A; Thirion S
    J Clin Endocrinol Metab; 2014 Dec; 99(12):E2463-71. PubMed ID: 25272306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas.
    Gatto F; Feelders RA; Franck SE; van Koetsveld PM; Dogan F; Kros JM; Neggers SJCMM; van der Lely AJ; Lamberts SWJ; Ferone D; Hofland LJ
    J Clin Endocrinol Metab; 2017 Jun; 102(6):2009-2018. PubMed ID: 28323931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential expression of microRNAs in GH-secreting pituitary adenomas.
    Mao ZG; He DS; Zhou J; Yao B; Xiao WW; Chen CH; Zhu YH; Wang HJ
    Diagn Pathol; 2010 Dec; 5():79. PubMed ID: 21138567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response.
    Fougner SL; Lekva T; Borota OC; Hald JK; Bollerslev J; Berg JP
    J Clin Endocrinol Metab; 2010 May; 95(5):2334-42. PubMed ID: 20335450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly.
    Colao A; Auriemma RS; Pivonello R
    Pituitary; 2016 Apr; 19(2):210-21. PubMed ID: 26290466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epithelial-Mesenchymal Transition in the Resistance to Somatostatin Receptor Ligands in Acromegaly.
    Gil J; Jordà M; Soldevila B; Puig-Domingo M
    Front Endocrinol (Lausanne); 2021; 12():646210. PubMed ID: 33790868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly.
    Potorac I; Petrossians P; Daly AF; Alexopoulou O; Borot S; Sahnoun-Fathallah M; Castinetti F; Devuyst F; Jaffrain-Rea ML; Briet C; Luca F; Lapoirie M; Zoicas F; Simoneau I; Diallo AM; Muhammad A; Kelestimur F; Nazzari E; Centeno RG; Webb SM; Nunes ML; Hana V; Pascal-Vigneron V; Ilovayskaya I; Nasybullina F; Achir S; Ferone D; Neggers SJ; Delemer B; Petit JM; Schöfl C; Raverot G; Goichot B; Rodien P; Corvilain B; Brue T; Schillo F; Tshibanda L; Maiter D; Bonneville JF; Beckers A
    Endocr Relat Cancer; 2016 Nov; 23(11):871-881. PubMed ID: 27649724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.
    Ibáñez-Costa A; Rivero-Cortés E; Vázquez-Borrego MC; Gahete MD; Jiménez-Reina L; Venegas-Moreno E; de la Riva A; Arráez MÁ; González-Molero I; Schmid HA; Maraver-Selfa S; Gavilán-Villarejo I; García-Arnés JA; Japón MA; Soto-Moreno A; Gálvez MA; Luque RM; Castaño JP
    J Endocrinol; 2016 Nov; 231(2):135-145. PubMed ID: 27587848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ZAC1 and SSTR2 are downregulated in non-functioning pituitary adenomas but not in somatotropinomas.
    Vieria Neto L; Wildemberg LE; Colli LM; Kasuki L; Marques NV; Moraes AB; Gasparetto EL; Takiya CM; Castro M; Gadelha MR
    PLoS One; 2013; 8(10):e77406. PubMed ID: 24098585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Effect of a Novel Chimeric Molecule Targeting Both Somatostatin and Dopamine Receptors on Growth Hormone-Secreting Pituitary Adenomas.
    Kim J; Oh JH; Harlem H; Culler MD; Ku CR; Lee EJ
    Endocrinol Metab (Seoul); 2020 Mar; 35(1):177-187. PubMed ID: 32207278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low levels of raf kinase inhibitory protein in growth hormone-secreting pituitary adenomas correlate with poor response to octreotide treatment.
    Fougner SL; Bollerslev J; Latif F; Hald JK; Lund T; Ramm-Pettersen J; Berg JP
    J Clin Endocrinol Metab; 2008 Apr; 93(4):1211-6. PubMed ID: 18230656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas.
    Plöckinger U; Albrecht S; Mawrin C; Saeger W; Buchfelder M; Petersenn S; Schulz S
    J Clin Endocrinol Metab; 2008 Apr; 93(4):1203-10. PubMed ID: 18198230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly.
    Neto LV; Machado Ede O; Luque RM; Taboada GF; Marcondes JB; Chimelli LM; Quintella LP; Niemeyer P; de Carvalho DP; Kineman RD; Gadelha MR
    J Clin Endocrinol Metab; 2009 Jun; 94(6):1931-7. PubMed ID: 19293270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway.
    Chahal HS; Trivellin G; Leontiou CA; Alband N; Fowkes RC; Tahir A; Igreja SC; Chapple JP; Jordan S; Lupp A; Schulz S; Ansorge O; Karavitaki N; Carlsen E; Wass JA; Grossman AB; Korbonits M
    J Clin Endocrinol Metab; 2012 Aug; 97(8):E1411-20. PubMed ID: 22659247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.